Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Oracle Corp. ( ORCL - Analyst Report ) is scheduled to announce its fiscal 2013 first quarter results after the closing bell on September 20, 2012. In the run up to the earnings release, we do not notice any significant revision in estimates by the analysts covering the stock. Oracle has outperformed the Zacks Consensus Estimate in the preceding four quarters by a positive 2.50%. We expect this trend to continue in the current quarter.
Previous Quarter Highlights
Oracle reported robust top-line growth in the fourth quarter of 2012 that helped the company earn 79 cents per share in the quarter, beating the Zacks Consensus Estimate by 3 cents.
Total revenue increased 1.3% year over year to $10.92 billion, driven by better-than-expected new software license revenues (up 6.6% year over year), fully offsetting a decline in hardware sales (down 13.8% year over year). The decline in hardware sales was primarily due to lower volumes.
For the first quarter of 2013, Oracle expects non-GAAP earnings in the range of 51 cents to 55 cents per share. Oracle expects total revenue growth on non-GAAP basis to range from -2.0% to 1.0% considering the current rates.
For further details please see: Oracle Beats Estimates in 4Q.
Estimate Revision Trend
Over the past 30 days, none of the 16 analysts covering the stock revised their estimates in either direction. Thus, the Zacks Consensus Estimate for the first quarter remained at 51 cents reflecting year-over-year earnings growth of 13.2%.
The Zacks Consensus Estimate for first quarter revenue is $8.42 billion, almost flat compared with $8.37 billion reported in the year-ago quarter.
Analysts expect Oracle to report an in-line quarter, driven by positive growth from new software sales and strength in middleware and database, which is expected to offset sluggish hardware sales in the near term.
Recommendation
Over the years, first quarter has been seasonally weak for Oracle. We expect this trend to continue in the current quarter. Nonetheless, we believe that Oracle possesses a strong product pipeline, which will drive broad-based top-line growth going forward.
We believe that speedy adoption of Exadata, Exalogic, Exalytics, the core SPARC product line and fusion systems will drive incremental top-line growth going ahead. Moreover, Oracle’s solid product suite lends a competitive edge over rivals like International Business Machines Corp. ( IBM - Analyst Report ) and SAP AG ( SAP - Analyst Report ) . We believe that the new public cloud offering, known as Oracle Cloud, will diversify its revenue base, thereby boosting top-line growth.
However, lower hardware volumes remain a concern in the near term. We believe that Oracle will take at least another three to four quarters to achieve top-line growth in the hardware segment.
As Oracle sells higher-margin products compared to its competitors, we anticipate that a sluggish market and lower IT spending may act as a headwind to hardware volumes going forward. Oracle could see integration issues due to the rapid pace of acquisitions within a short span of time.
We maintain a long-term Neutral recommendation on Oracle. Currently, Oracle has a Zacks #3 Rank, which implies a Hold rating on a short-term basis.
Read the full reports :
Analyst Report on IBM
Analyst Report on SAP
Analyst Report on ORCL